drugset / Trial / NCT05010876
Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).
RandomizedParallel-groupDouble-blindTreatment
Summary
The main objective of this study is to evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections.
Timeline
- Start
- 2021-02-04
- Primary completion
- 2021-06-13
- Completion
- 2021-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CINRYZE | Protein / enzyme biologic | 1000 iu | Other |
| Subject | Icatibant | Peptide | 30 mg | Subcutaneous |